Bank­ing on in­te­grase in­hibitors as HIV cor­ner­stone, Vi­iV bags 3rd-gen­er­a­tion com­pound from Sh­iono­gi

As a 12% share­hold­er of Vi­iV Health­care, Japan’s Sh­iono­gi has com­mand­ed a much low­er pro­file than its fel­low own­ers, Glax­o­SmithK­line and Pfiz­er. But be­hind the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER